D. E. Shaw & Co., Inc. Bio N Tech Se Call Options Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$78.36 - $124.66 $1.64 Million - $2.61 Million	20,900 Added 94.57%	43,000 $5.11 Million
Q2 2024 Aug 14, 2024	BUY	$80.36 - $102.87 $329,476 - $421,767	4,100 Added 22.78%	22,100 $1.78 Million
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $1.6 Million - $2.02 Million	18,000 New	18,000 $1.66 Million
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $4.93 Million - $7.45 Million	-40,000 Reduced 53.33%	35,000 $5.22 Million
Q1 2022 May 16, 2022	SELL	$126.25 - $231.85 $1.26 Million - $2.32 Million	-10,000 Reduced 11.76%	75,000 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$216.64 - $362.52 $6.5 Million - $10.9 Million	30,000 Added 54.55%	85,000 $21.9 Million
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $2.06 Million - $4.47 Million	10,000 Added 22.22%	55,000 $15 Million
Q2 2021 Aug 16, 2021	BUY	$113.32 - $241.49 $5.1 Million - $10.9 Million	45,000 New	45,000 $10.1 Million

360

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $30B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.